N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1 Purity >99.0% (HPLC) Afatinib Dimaleate Intermediate Factory

Short Description:

Chemical Name: N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine 

CAS: 162012-67-1

Purity: >99.0% (HPLC) 

Appearance: Light Yellow to Yellow Powder

Intermediate of Afatinib Dimaleate (CAS: 850140-73-7)

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine
Synonyms N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitro-4-Quinazolinamine; (3-Chloro-4-Fluorophenyl)(7-Fluoro-6-Nitroquinazolin-4-yl)amine; 4-(3-Chloro-4-Fluoroanilino)-7-Fluoro-6-Nitroquinazoline; Afatinib Intermediate A
CAS Number 162012-67-1
CAT Number RF-PI2026
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C14H7ClF2N4O2
Molecular Weight 336.68  
Sensitivity Air Sensitive, Heat Sensitive
Melting Point  242.0~244.0℃
Boiling Point 489℃
Density 1.616
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Light Yellow to Yellow Powder
Purity / Analysis Method >99.0% (HPLC)   
Loss on Drying <0.50%
Residue on Ignition <0.20%
Related Substances
Individual Impurity <0.50%
Total Impurities <1.00%
Heavy Metals ≤20ppm
Infrared Spectrum Conforms to Structure
Proton NMR Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of Afatinib Dimaleate (CAS: 850140-73-7)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine (CAS: 162012-67-1) is an intermediate in the synthesis of Afatinib Dimaleate (CAS: 850140-73-7). Afatinib Dimaleate is a salt form of Afatinib. Afatinib is a second-generation, orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases. Mechanism of ActionAfatinib downregulates ErbB signalling by covalently binding to the kinase domains of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, resulting in irreversible inhibition of tyrosine kinase autophosphorylation; it also inhibits transphosphorylation of HER3. Afatinib is approved as monotherapy for the treatment of EGFR tyrosine kinase inhibitor (TKI)-naive adults with locally advanced or DefinitionChEBI: A maleate salt obtained by combining afatinib with two molar equivalents of maleic acid. Used for the first-line treatment of patients with metastatic non-small cell lung cancer.

  • Write your message here and send it to us